Shreveport, LA, United States of America

Tony Giordano

USPTO Granted Patents = 3 



Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2011-2014

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Tony Giordano

Introduction

Tony Giordano is a notable inventor based in Shreveport, Louisiana. He has made significant contributions to the field of pharmaceuticals, particularly through his work on thalidomide analogs. With a total of three patents to his name, Giordano's innovations are aimed at modulating tumor necrosis factor alpha (TNF-α) activity and angiogenesis.

Latest Patents

Giordano's latest patents focus on thalidomide analogs that have the potential to modulate TNF-α activity and angiogenesis. These analogs are particularly noteworthy as they are isosteric sulfur-containing compounds. The patents also disclose methods for treating subjects with these innovative analogs, showcasing their potential therapeutic applications.

Career Highlights

Throughout his career, Tony Giordano has worked with various organizations, including P2D, Inc. and the National Institutes of Health, which is a component of the U.S. Department of Health & Human Services. His work in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Giordano has collaborated with esteemed colleagues such as Nigel H. Greig and Harold W. Holloway. These partnerships have likely enriched his research and led to further advancements in his field.

Conclusion

Tony Giordano's innovative work in developing thalidomide analogs demonstrates his commitment to advancing medical science. His contributions have the potential to impact treatment options for various conditions, highlighting the importance of his research in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…